{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:39:54Z","timestamp":1791146394404,"version":"4.1.0"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1097\/bor.0b013e328099af80","type":"journal-article","created":{"date-parts":[[2007,4,2]],"date-time":"2007-04-02T08:04:10Z","timestamp":1175501050000},"page":"238-245","source":"Crossref","is-referenced-by-count":105,"title":["Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis"],"prefix":"10.1097","volume":"19","author":[{"given":"Kanako","family":"Kitahara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210128","article-title":"Rheumatoid arthritis","author":"Gorzony","year":"2001"},{"key":"R2-3-20210128","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/art.10148","article-title":"American College of Rheumatology. Guidelines for the management of rheumatoid arthritis: 2002 update","volume":"46","author":"Newsome","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R3-3-20210128","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0049-0172(96)80016-3","article-title":"Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model","volume":"25","author":"Kavanaugh","year":"1996","journal-title":"Semin Arthritis Rheum"},{"key":"R4-3-20210128","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM198912213212507","article-title":"Cyclosporine","volume":"321","author":"Kahan","year":"1989","journal-title":"N Engl J Med"},{"key":"R5-3-20210128","first-page":"205","article-title":"The superiority of tacrolimus in renal transplant recipients - the Pittsburgh experience.","volume":"199-","author":"Shapiro","year":"1995","journal-title":"Clin Transpl"},{"key":"R6-3-20210128","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1089-3261(05)70278-6","article-title":"Cyclosporine and tacrolimus: the mainstay of immunosuppressive therapy for solid organ transplantation.","volume":"1","author":"Testa","year":"1997","journal-title":"Clin Liver Dis"},{"key":"R7-3-20210128","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF01973261","article-title":"Biological effects of cyclosporin A: a new antilymphocytic agent","volume":"6","author":"Borel","year":"1976","journal-title":"Agents Actions"},{"key":"R8-3-20210128","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.7164\/antibiotics.40.1256","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro","volume":"40","author":"Kino","year":"1987","journal-title":"J Antibiot"},{"key":"R9-3-20210128","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0171-2985(97)80040-X","article-title":"Effects of the immunosuppressive drugs CsA and FK506 on intracellular signalling and gene regulation","volume":"198","author":"Ruhlmann","year":"1997","journal-title":"Immunobiology"},{"key":"R10-3-20210128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.1993.tb17137.x","article-title":"The mechanism of action of FK-506 and cyclosporin A","volume":"696","author":"Wiederrecht","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"R11-3-20210128","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/ajhp\/52.14.1521","article-title":"Tacrolimus: a new immunosuppressive agent","volume":"52","author":"Kelly","year":"1995","journal-title":"Am J Health Syst Pharm"},{"key":"R12-3-20210128","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2174\/1568026033451862","article-title":"Peptidylprolyl cis\/trans isomerases (immunophilins): biological diversity\u2013targets\u2013functions","volume":"3","author":"Galat","year":"2003","journal-title":"Curr Topics Med Chem"},{"key":"R13-3-20210128","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.2174\/0929867033457160","article-title":"Cyclophilin D as a drug target","volume":"10","author":"Waldmeier","year":"2003","journal-title":"Curr Med Chem"},{"key":"R14-3-20210128","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.2174\/1568026033451899","article-title":"Structures of immunophilins and their ligand complexes","volume":"3","author":"Dornan","year":"2003","journal-title":"Curr Topics Med Chem"},{"key":"R15-3-20210128","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0014-5793(96)01248-3","article-title":"A nuclear RNA-binding cyclophilin in human T cells","volume":"398","author":"Mi","year":"1996","journal-title":"FEBS Lett"},{"key":"R16-3-20210128","doi-asserted-by":"crossref","first-page":"12303","DOI":"10.1016\/S0021-9258(18)31389-9","article-title":"Cyclophilin-40, a protein with homology to the p59 component of the steroid receptor complex. Cloning of the cDNA and further characterization","volume":"268","author":"Kieffer","year":"1993","journal-title":"J Biol Chem"},{"key":"R17-3-20210128","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1073\/pnas.90.2.542","article-title":"A cyclophilin-related protein involved in the function of natural killer cells","volume":"90","author":"Anderson","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R18-3-20210128","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1021\/bi00173a008","article-title":"The N-terminal cyclophilin-homologous domain of a 150-kilodalton tumor recognition molecule exhibits both peptidylprolyl cis\u2013trans-isomerase and chaperone activities","volume":"33","author":"Rinfret","year":"1994","journal-title":"Biochemistry"},{"key":"R19-3-20210128","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s00335-005-0127-7","article-title":"The human FK506-binding proteins: characterization of human FKBP19","volume":"17","author":"Rulten","year":"2006","journal-title":"Mamm Genome"},{"key":"R20-3-20210128","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1097\/00007890-199506000-00018","article-title":"Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell","volume":"59","author":"Tamura","year":"1995","journal-title":"Transplantation"},{"key":"R21-3-20210128","doi-asserted-by":"crossref","first-page":"11850","DOI":"10.1073\/pnas.90.24.11850","article-title":"Crystal structure of murine cyclophilin C complexed with immunosuppressive drug cyclosporin A","volume":"90","author":"Ke","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R22-3-20210128","doi-asserted-by":"crossref","first-page":"8218","DOI":"10.1021\/bi00193a007","article-title":"Human cyclophilin C: primary structure, tissue distribution, and determination of binding specificity for cyclosporins","volume":"33","author":"Schneider","year":"1994","journal-title":"Biochemistry"},{"key":"R23-3-20210128","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/1529-0131(200201)46:1<42::AID-ART10026>3.0.CO;2-A","article-title":"Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor a production by rheumatoid synoviocytes","volume":"46","author":"Cho","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R24-3-20210128","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/art.10215","article-title":"Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts","volume":"46","author":"Cho","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R25-3-20210128","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.imlet.2004.11.014","article-title":"FK506 suppresses the stimulation of matrix metalloproteinase 13 synthesis by interleukin-1beta in rheumatoid synovial fibroblasts","volume":"98","author":"Migita","year":"2005","journal-title":"Immunol Lett"},{"key":"R26-3-20210128","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.intimp.2005.03.014","article-title":"FK506 inhibits prostaglandin E2 production from synovial cells by suppressing peripheral blood mononuclear cells","volume":"5","author":"Sasakawa","year":"2005","journal-title":"Int Immunopharmacol"},{"key":"R27-3-20210128","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.4049\/jimmunol.177.4.2681","article-title":"Calcineurin is expressed and plays a critical role in inflammatory arthritis","volume":"177","author":"Yoo","year":"2006","journal-title":"J Immunol"},{"key":"R28-3-20210128","first-page":"2193","article-title":"Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis","volume":"30","author":"Magari","year":"2003","journal-title":"J Rheumatol"},{"key":"R29-3-20210128","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00011-004-1284-y","article-title":"Inflammatory cytokine levels in paw tissues during development of rat collagen-induced arthritis: effect of FK506, an inhibitor of T cell activation","volume":"53","author":"Magari","year":"2004","journal-title":"Inflamm Res"},{"key":"R30-3-20210128","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00011-003-1210-8","article-title":"Antiarthritic properties of FK506 on collagen-induced arthritis in rats","volume":"52","author":"Magari","year":"2003","journal-title":"Inflamm Res"},{"key":"R31-3-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00011-004-1318-5","article-title":"A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis","volume":"54","author":"Miyata","year":"2005","journal-title":"Inflamm Res"},{"key":"R32-3-20210128","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10067-006-0287-1","article-title":"Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis","volume":"26","author":"Miyazaki","year":"2007","journal-title":"Clin Rheumatol"},{"key":"R33-3-20210128","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.pharmthera.2006.04.006","article-title":"An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients","volume":"112","author":"Masuda","year":"2006","journal-title":"Pharmacol Ther"},{"key":"R36-3-20210128","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1373\/clinchem.2005.050047","article-title":"Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus","volume":"51","author":"Kamdem","year":"2005","journal-title":"Clin Chem"},{"key":"R37-3-20210128","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/14622416.6.1.37","article-title":"Cytochrome P450 3A polymorphisms and immunosuppressive drugs","volume":"6","author":"Thervet","year":"2005","journal-title":"Pharmacogenomics"},{"key":"R38-3-20210128","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1124\/dmd.31.12.1526","article-title":"A significant drug-metabolizing role for CYP3A5?","volume":"31","author":"Williams","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"R39-3-20210128","first-page":"173","article-title":"Therapy of rheumatoid arthritis with cyclosporin A, a new immunosuppressive drug","volume":"4","author":"Herrmann","year":"1979","journal-title":"Aktuelle Rheumatol"},{"key":"R40-3-20210128","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/rheumatology\/36.7.808","article-title":"The use of cyclosporin A microemulsion in rheumatoid arthritis: conclusions of an international review","volume":"36","author":"Panayi","year":"1997","journal-title":"Br J Rheumatol"},{"key":"R41-3-20210128","first-page":"1176","article-title":"US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis","volume":"26","author":"Cush","year":"1999","journal-title":"J Rheumatol"},{"key":"R42-3-20210128","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJM199507203330301","article-title":"Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate\u2013Cyclosporine Combination Study Group","volume":"333","author":"Tugwell","year":"1995","journal-title":"N Engl J Med"},{"key":"R43-3-20210128","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/rheumatology\/35.11.1142","article-title":"Adding low-dose cyclosporin A to parenteral gold therapy in rheumatoid arthritis: a double-blind placebo-controlled study","volume":"35","author":"Bendix","year":"1996","journal-title":"Br J Rheumatol"},{"key":"R44-3-20210128","first-page":"1493","article-title":"Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine","volume":"25","author":"Van den Borne","year":"1998","journal-title":"J Rheumatol"},{"key":"R45-3-20210128","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/rheumatology\/keg394","article-title":"Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone","volume":"42","author":"Marchesoni","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"R46-3-20210128","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/ard.62.4.291","article-title":"Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial","volume":"62","author":"Gerards","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R47-3-20210128","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.arcmed.2003.07.008","article-title":"A randomized, double-blind, multicenter, controlled clinical trial of cyclosporine plus chloroquine vs. cyclosporine plus placebo in early-onset rheumatoid arthritis","volume":"35","author":"Miranda","year":"2004","journal-title":"Arch Med Res"},{"key":"R48-3-20210128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00296-003-0384-2","article-title":"An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis","volume":"25","author":"Sarzi-Puttini","year":"2005","journal-title":"Rheumatol Int"},{"key":"R49-3-20210128","first-page":"486","article-title":"Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis","volume":"33","author":"Karanikolas","year":"2006","journal-title":"J Rheumatol"},{"key":"R50-3-20210128","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/art.21796","article-title":"Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: An investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study","volume":"54","author":"Hetland","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R51-3-20210128","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1136\/ard.2005.036152","article-title":"An open label, single dose study to evaluate the safety, efficacy, and effects on CD25 expression of cyclosporin in patients with active rheumatoid arthritis despite treatment with methotrexate and infliximab","volume":"65","author":"Sidiropoulos","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R52-3-20210128","first-page":"2332","article-title":"Tacrolimus (FK506) in the treatment of severe, refractory rheumatoid arthritis: initial experience in 12 patients","volume":"26","author":"Gremillion","year":"1999","journal-title":"J Rheumatol"},{"key":"R53-3-20210128","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/art.10427","article-title":"Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study","volume":"46","author":"Furst","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R54-3-20210128","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1002\/art.11257","article-title":"Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study","volume":"48","author":"Kremer","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R55-3-20210128","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1002\/art.11363","article-title":"Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial","volume":"48","author":"Yocum","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R56-3-20210128","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/rheumatology\/keh155","article-title":"Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience","volume":"43","author":"Yocum","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"R57-3-20210128","first-page":"243","article-title":"Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study","volume":"31","author":"Kondo","year":"2004","journal-title":"J Rheumatol"},{"key":"R58-3-20210128","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/rheumatology\/kei172","article-title":"Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients","volume":"45","author":"Kawai","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R59-3-20210128","first-page":"2153","article-title":"Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis","volume":"33","author":"Kawai","year":"2006","journal-title":"J Rheumatol"},{"key":"R60-3-20210128","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/00007890-199708150-00012","article-title":"Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group","volume":"64","author":"Mayer","year":"1997","journal-title":"Transplantation"},{"key":"R61-3-20210128","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/00007890-199704150-00013","article-title":"A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group","volume":"63","author":"Pirsch","year":"1997","journal-title":"Transplantation"},{"key":"R62-3-20210128","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0041-1345(98)00246-2","article-title":"Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients","volume":"30","author":"Claesson","year":"1998","journal-title":"Transplant Proc"},{"key":"R63-3-20210128","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0041-1345(98)00216-4","article-title":"Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the us multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group","volume":"30","author":"Jensik","year":"1998","journal-title":"Transplant Proc"},{"key":"R64-3-20210128","first-page":"2102","article-title":"Cyclosporine A in rheumatoid arthritis: randomized, placebo controlled dose finding study","volume":"26","author":"Altman","year":"1999","journal-title":"J Rheumatol"},{"key":"R65-3-20210128","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2125.1999.00007.x","article-title":"Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients","volume":"48","author":"Bottiger","year":"1999","journal-title":"Br J Clin Pharmacol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0b013e328099af80","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T22:55:15Z","timestamp":1620946515000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-200705000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e328099af80","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}